Genzyme reorganization?
Executive Summary
Genzyme CEO Henri Termeer was asked several times during April 16 conference call about the company's capital structure in light of recent concerns about tracking stocks and corporate accounting. "We are always looking at the capital structure of the company. We are doing that now and will be looking at doing that in the future," Termeer says. Pressed for further comment, Termeer says, "this is an earnings call, not a structure call"...
You may also be interested in...
Genzyme ends tracking-stock structure
Genzyme will exchange shares of Genzyme Biosurgery stock and Genzyme Molecular Oncology stock for shares of Genzyme General stock on June 30. "We do not expect to make any major changes within our business or research programs at this time," CEO Henri Termeer says. Termeer was asked about the company's capital structure in light of concerns about tracking stocks and corporate accounting during an April 16 earnings call (1"The Pink Sheet" April 28, In Brief)...
DJO Thinks Trilliant Is Brilliant, Announces Acquisition
DJO Global will buy Trilliant Surgical to further its ongoing expansion into the US foot and ankle market.
Legend Biotech CEO Ying Huang On Moving Fast In the BCMA CAR-T Race
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: